Galectin Therapeutics INC (GALT) — 10-Q Filings

10-Q Filings (5)

• Galectin Therapeutics Narrows Loss Amidst R&D Cut, Bolstered by Insider Loan — Nov 14, 2025 Risk: high
  GALECTIN THERAPEUTICS INC. reported a net loss of $8.184 million for the three months ended September 30, 2025, an improvement from a net loss of $11.220 millio
• Galectin Therapeutics Narrows Losses Amid R&D Cuts, Secures New Funding — Aug 14, 2025 Risk: high
  GALECTIN THERAPEUTICS INC. reported a net loss of $7.521 million for the three months ended June 30, 2025, a significant improvement from the $12.371 million ne
• Galectin Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Galectin Therapeutics Inc. filed its Q3 2024 10-Q report on November 14, 2024, detailing its financial performance for the period ending September 30, 2024. The
• Galectin Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Galectin Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial condition and business operations. The company, former
• Galectin Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  GALECTIN THERAPEUTICS INC (GALT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Galectin Therapeutics Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX